Synopsis on the Linkage of Alzheimer's and Parkinson's Disease with Chronic Diseases

CNS Neuroscience and Therapeutics

Volumn 21, Issue 1, 2015, Pages 1-7

  Jabir, Nasimudeen R ^a   Firoz, Chelapram K ^a   Baeesa, Saleh S ^a   Ashraf, Ghulam Md ^a   Akhtar, Suhail ^b   Kamal, Warda ^c   Kamal, Mohammad A ^a   Tabrez, Shams ^a  

^a KING ABDULAZIZ UNIVERSITY   (Saudi Arabia)

^b NORTHWESTERN UNIVERSITY   (United States)

^c Biomediotronics   (Australia)

Author keywords

Alzheimer's disease; Cancer; Cardiovascular disease; Neurodegenerative disorders; Parkinson's disease

Indexed keywords

ALZHEIMER DISEASE; CARDIOVASCULAR DISEASE; CHRONIC DISEASE; DIABETES MELLITUS; GENETIC LINKAGE; HUMAN; NEOPLASM; OXIDATIVE STRESS; PARKINSON DISEASE; REVIEW; ANIMAL; PATHOPHYSIOLOGY;

ALZHEIMER DISEASE; ANIMALS; CARDIOVASCULAR DISEASES; CHRONIC DISEASE; DIABETES MELLITUS; HUMANS; NEOPLASMS; PARKINSON DISEASE;

EID: 84918533616     PISSN: 17555930     EISSN: 17555949     Source Type: Journal    
DOI: 10.1111/cns.12344     Document Type: Review

References (134)

1. Cannon JR, Greenamyre JT. The role of environmental exposures in neurodegeneration and neurodegenerative diseases. Toxicol Sci 2011;124:225-250.
2. Son JH, Shim JH, Kim K-H, Ha J-Y, Han JY. Neuronal autophagy and neurodegenerative diseases. Exp Mol Med 2012;44:89-98.
3. Robillard JM, Federico CA, Tairyan K, Ivinson AJ, Illes J. Untapped ethical resources for neurodegeneration research. BMC Med Ethics 2011;12:9.
4. Ballard C, Gauthier S, Corbett A, Brayne C, Aarsland D, Jones E. Alzheimer's disease. Lancet 2011;377:1019-1031.
5. Ergin V, Hariry RE, Karasu C. Carbonyl stress in aging process: Role of vitamins and phytochemicals as redox regulators. Aging Dis 2013;4:276-294.
6. Tosato M, Zamboni V, Ferrini A, Cesari M. The aging process and potential interventions to extend life expectancy. Clin Interv Aging 2007;2:401-412.
7. Lee SH, Lee SK, Paik D, Min KJ. Overexpression of fatty-acid-?-oxidation-related genes extends the lifespan of drosophila melanogaster. Oxid Med Cell Longev 2012;2012:854502.
8. Makpol S, Zainuddin A, Chua KH, Mohd Yusof YA, Ngah WZW. Gamma-Tocotrienol modulated gene expression in senescent human diploid fibroblasts as revealed by microarray analysis. Oxid Med Cell Longev 2013;2013:454328.
9. Leclère R, Torregrosa-Muñumer R, Kireev R, et al. Effect of estrogens on base excision repair in brain and liver mitochondria of aged female rats. Biogerontology 2013;14:383-394.
10. Ohshima S. Centrosome aberrations associated with cellular senescence and p53 localization at supernumerary centrosomes. Oxid Med Cell Longev 2012;2012:217594.
11. Mangerich A, Bürkle A. Pleiotropic cellular functions of PARP1 in longevity and aging: Genome maintenance meets inflammation. Oxid Med Cell Longev 2012;2012:321653.
12. de Magalhães JP, Wuttke D, Wood SH, Plank M, Vora C. Genome-environment interactions that modulate aging: Powerful targets for drug discovery. Pharmacol Rev 2012;64:88-101.
13. Reid MB, Durham WJ. Generation of reactive oxygen and nitrogen species in contracting skeletal muscle: Potential impact on aging. Ann N Y Acad Sci 2002;959:108-116.
14. Jackson MJ. Interactions between reactive oxygen species generated by contractile activity and aging in skeletal muscle? Antioxid Redox Signal 2013;19:804-812.
15. Jackson MJ, McArdle A. Age-related changes in skeletal muscle reactive oxygen species generation and adaptive responses to reactive oxygen species. J Physiol 2011;589:2139-2145.
16. Roe CM, Fitzpatrick AL, Xiong C, et al. Cancer linked to Alzheimer disease but not vascular dementia. Neurology 2010;74:106-112.
17. Venkataramani V, Rossner C, Iffland L, et al. Histone deacetylase inhibitor valproic acid inhibits cancer cell proliferation via down-regulation of the alzheimer amyloid precursor protein. J Biol Chem 2010;285:10678-10689.
18. Lima MMS, Targa ADS, Noseda ACD, et al. Does Parkinson's disease and type-2 diabetes mellitus present common pathophysiological mechanisms and treatments? CNS Neurol Disord Drug Targets 2014;13:418-428.
19. Doraiswamy PM, Leon J, Cummings JL, Marin D, Neumann PJ. Prevalence and impact of medical comorbidity in Alzheimer's disease. J Gerontol A Biol Sci Med Sci 2002;57:M173-M177.
20. Zamrini E, Parrish JA, Parsons D, Harrell LE. Medical comorbidity in black and white patients with Alzheimer's disease. South Med J 2004;97:2-6.
21. Qiu C, Hu G, Kivipelto M, et al. Association of blood pressure and hypertension with the risk of Parkinson disease: The National FINRISK Study. Hypertension 2011;57:1094-1100.
22. Duthie A, Chew D, Soiza RL. Non-psychiatric comorbidity associated with Alzheimer's disease. QJM 2011;104:913-920.
23. Larson EB, Shadlen M-F, Wang L, et al. Survival after initial diagnosis of Alzheimer disease. Ann Intern Med 2004;140:501-509.
24. Uttara B, Singh AV, Zamboni P, Mahajan RT. Oxidative stress and neurodegenerative diseases: A review of upstream and downstream antioxidant therapeutic options. Curr Neuropharmacol 2009;7:65-74.
25. Acharya A, Das I, Chandhok D, Saha T. Redox regulation in cancer. Oxid Med Cell Longev 2010;3:23-34.
26. Pala FS, Gürkan H. The role of free radicals in ethiopathogenesis of diseases. Adv Mol Biol 2008;1:1-9.
27. Friedlander RM. Apoptosis and caspases in neurodegenerative diseases. N Engl J Med 2003;348:1365-1375.
28. Kitamura Y, Shimohama S, Kamoshima W, Matsuoka Y, Nomura Y, Taniguchi T. Changes of p53 in the brains of patients with Alzheimer's disease. Biochem Biophys Res Commun 1997;232:418-421.
29. Dhanasekaran M, Ren J. The emerging role of coenzyme Q-10 in aging, neurodegeneration, cardiovascular disease, cancer and diabetes mellitus. Curr Neurovasc Res 2005;2:447-459.
30. Khan MS, Tabrez S, Priyadarshini M, Priyamvada S, Khan MM. Targeting Parkinson's - tyrosine hydroxylase and oxidative stress as points of interventions. CNS Neurol Disord Drug Targets 2012;11:369-380.
31. Thomas B, Beal MF. Parkinson's disease. Hum Mol Genet 2007;16:R183-R194.
32. Evans JL, Goldfine ID, Maddux BA, Grodsky GM. Are oxidative stress-activated signaling pathways mediators of insulin resistance and β-cell dysfunction? Diabetes 2003;52:1-8.
33. Rösen P, Nawroth PP, King G, Möller W, Tritschler HJ, Packer L. The role of oxidative stress in the onset and progression of diabetes and its complications: A summary of a Congress Series sponsored by UNESCO-MCBN, the American Diabetes Association and the German Diabetes Society. Diabetes Metab Res Rev 2001;17:189-212.
34. Koya D, King GL. Protein kinase C activation and the development of diabetic complications. Diabetes 1998;47:859-866.
35. Giacco F, Brownlee M. Oxidative stress and diabetic complications. Circ Res 2010;107:1058-1070.
36. Kamal MA, Priyamvada S, Anbazhagan AN, Jabir NR, Tabrez S, Greig NH. Linking Alzheimer's disease and type 2 diabetes mellitus via aberrant insulin signaling and inflammation. CNS Neurol Disord Drug Targets 2014;13:338-346.
37. Folli F, Corradi D, Fanti P, et al. The role of oxidative stress in the pathogenesis of type 2 diabetes mellitus micro- and macrovascular complications: Avenues for a mechanistic-based therapeutic approach. Curr Diabetes Rev 2011;7:313-324.
38. Simone S, Gorin Y, Velagapudi C, Abboud HE, Habib SL. Mechanism of oxidative DNA damage in diabetes. Diabetes 2008;57:2626-2636.
39. Johnson JD, Luciani DS. Mechanisms of pancreatic beta-cell apoptosis in diabetes and its therapies. Adv Exp Med Biol 2010;654:447-462.
40. Maedler K, Donath MY. Beta-cells in type 2 diabetes: A loss of function and mass. Horm Res 2004;62:67-73.
41. Palacios N, Gao X, McCullough ML, et al. Obesity, diabetes, and risk of Parkinson's disease. Mov Disord 2011;26:2253-2259.
42. Sun Y, Chang Y-H, Chen H-F, Su Y-H, Su H-F, Li C-Y. Risk of Parkinson disease onset in patients with diabetes: A 9-year population-based cohort study with age and sex stratifications. Diabetes Care 2012;35:1047-1049.
43. Driver JA, Smith A, Buring JE, Gaziano JM, Kurth T, Logroscino G. Prospective cohort study of type 2 diabetes and the risk of Parkinson's disease. Diabetes Care 2008;31:2003-2005.
44. Hu G, Jousilahti P, Bidel S, Antikainen R, Tuomilehto J. Type 2 diabetes and the risk of Parkinson's disease. Diabetes Care 2007;30:842-847.
45. Cereda E, Barichella M, Pedrolli C, et al. Diabetes and risk of Parkinson's disease: A systematic review and meta-analysis. Diabetes Care 2011;34:2614-2623.
46. Xu Q, Park Y, Huang X, et al. Diabetes and risk of Parkinson's disease. Diabetes Care 2011;34:910-915.
47. Santiago JA, Potashkin JA. Integrative network analysis unveils convergent molecular pathways in Parkinson's disease and diabetes. PLoS One 2013;8:e83940.
48. Aviles-Olmos I, Limousin P, Lees A, Foltynie T. Parkinson's disease, insulin resistance and novel agents of neuroprotection. Brain 2013;136:374-384.
49. Zheng B, Liao Z, Locascio JJ, et al. PGC-1α, a potential therapeutic target for early intervention in Parkinson's disease. Sci Transl Med 2010;2:52ra73.
50. Upadhaya AR, Kosterin I, Kumar S, et al. Biochemical stages of amyloid-β peptide aggregation and accumulation in the human brain and their association with symptomatic and pathologically preclinical Alzheimer's disease. Brain 2014;137:887-903.
51. Jabir NR, Kamal MA, Abuzenadah AM, et al. Alzheimer's and type 2 diabetes treatment via common enzyme targeting. CNS Neurol Disord Drug Targets 2014;13:299-304.
52. Mushtaq G, Khan JA, Kumosani TA, Kamal MA. Alzheimer's disease and type 2 diabetes via chronic inflammatory mechanisms. Saudi J Biol Sci 2014. In Press: DOI: 10.1016/j.sjbs.2014.05.1003.
53. Costes S, Langen R, Gurlo T, Matveyenko AV, Butler PC. β-cell failure in type 2 diabetes: A case of asking too much of too few? Diabetes 2013;62:327-335.
54. Bomfim TR, Forny-Germano L, Sathler LB, et al. An anti-diabetes agent protects the mouse brain from defective insulin signaling caused by Alzheimer's disease- associated Aβ oligomers. J Clin Invest 2012;122:1339-1353.
55. Devi L, Alldred MJ, Ginsberg SD, Ohno M. Mechanisms underlying insulin deficiency-induced acceleration of β-amyloidosis in a mouse model of Alzheimer's disease. PLoS One 2012;7:e32792.
56. Ho L, Qin W, Pompl PN, et al. Diet-induced insulin resistance promotes amyloidosis in a transgenic mouse model of Alzheimer's disease. FASEB J 2004;18:902-904.
57. Jolivalt CG, Hurford R, Lee CA, Dumaop W, Rockenstein E, Masliah E. Type 1 diabetes exaggerates features of Alzheimer's disease in APP transgenic mice. Exp Neurol 2010;223:422-431.
58. Wang X, Zheng W, Xie J-W, et al. Insulin deficiency exacerbates cerebral amyloidosis and behavioral deficits in an Alzheimer transgenic mouse model. Mol Neurodegener 2010;5:46.
59. Jolivalt CG, Calcutt NA, Masliah E. Similar pattern of peripheral neuropathy in mouse models of type 1 diabetes and Alzheimer's disease. Neuroscience 2012;202:405-412.
60. Candeias E, Duarte AI, Carvalho C, et al. The impairment of insulin signaling in Alzheimer's disease. IUBMB Life 2012;64:951-957.
61. Janson J, Laedtke T, Parisi JE, O'Brien P, Petersen RC, Butler PC. Increased risk of type 2 diabetes in Alzheimer disease. Diabetes 2004;53:474-481.
62. Giuffrida ML, Tomasello F, Caraci F, Chiechio S, Nicoletti F, Copani A. Beta-amyloid monomer and insulin/IGF-1 signaling in Alzheimer's disease. Mol Neurobiol 2012;46:605-613.
63. Frölich L, Blum-Degen D, Bernstein HG, et al. Brain insulin and insulin receptors in aging and sporadic Alzheimer's disease. J Neural Transm 1998;105:423-438.
64. Steen E, Terry BM, Rivera EJ, et al. Impaired insulin and insulin-like growth factor expression and signaling mechanisms in Alzheimer's disease-is this type 3 diabetes? J Alzheimers Dis 2005;7:63-80.
65. Zhao W-Q, Lacor PN, Chen H, et al. Insulin receptor dysfunction impairs cellular clearance of neurotoxic oligomeric a{beta}. J Biol Chem 2009;284:18742-18753.
66. Carro E, Trejo JL, Gomez-Isla T, LeRoith D, Torres-Aleman I. Serum insulin-like growth factor I regulates brain amyloid-beta levels. Nat Med 2002;8:1390-1397.
67. Tabrez S, Priyadarshini M, Priyamvada S, Khan MS, Na A, Zaidi SK. Gene-environment interactions in heavy metal and pesticide carcinogenesis. Mutat Res 2014;760:1-9.
68. Valko M, Rhodes CJ, Moncol J, Izakovic M, Mazur M. Free radicals, metals and antioxidants in oxidative stress-induced cancer. Chem Biol Interact 2006;160:1-40.
69. Cooke MS, Evans MD, Dizdaroglu M, Lunec J. Oxidative DNA damage: Mechanisms, mutation, and disease. FASEB J 2003;17:1195-1214.
70. Perše M. Oxidative stress in the pathogenesis of colorectal cancer: Cause or consequence? Biomed Res Int 2013;2013:725710.
71. Bailey DT, DeFedericis H-CC, Greene KF, et al. A novel approach to DNA damage assessments: Measurement of the thymine glycol lesion. Radiat Res 2006;165:438-444.
72. Gonfloni S, Maiani E, Di Bartolomeo C, Diederich M, Cesareni G. Oxidative stress, DNA damage, and c-Abl signaling: At the crossroad in neurodegenerative diseases? Int J Cell Biol 2012;2012:683097.
73. Favaloro B, Allocati N, Graziano V, Di Ilio C, De Laurenzi V. Role of apoptosis in disease. Aging (Albany NY) 2012;4:330-349.
74. Shimohama S. Apoptosis in Alzheimer's disease-an update. Apoptosis 2000;5:9-16.
75. Serrano-Pozo A, Frosch MP, Masliah E, Hyman BT. Neuropathological alterations in Alzheimer disease. Cold Spring Harb Perspect Med 2011;1:a006189.
76. Loo DT, Copani A, Pike CJ, Whittemore ER, Walencewicz AJ, Cotman CW. Apoptosis is induced by beta-amyloid in cultured central nervous system neurons. Proc Natl Acad Sci U S A 1993;90:7951-7955.
77. McShea A, Harris PL, Webster KR, Wahl AF, Smith MA. Abnormal expression of the cell cycle regulators P16 and CDK4 in Alzheimer's disease. Am J Pathol 1997;150:1933-1939.
78. Tatton WG, Chalmers-Redman R, Brown D, Tatton N. Apoptosis in Parkinson's disease: Signals for neuronal degradation. Ann Neurol 2003;53:S61-S70.
79. Jope RS, Yuskaitis CJ, Beurel E. Glycogen synthase kinase-3 (GSK3): Inflammation, diseases, and therapeutics. Neurochem Res 2007;32:577-595.
80. Li T, Wen H, Brayton C, et al. Moderate reduction of gamma-secretase attenuates amyloid burden and limits mechanism-based liabilities. J Neurosci 2007;27:10849-10859.
81. Zheng H, Koo EH. Biology and pathophysiology of the amyloid precursor protein. Mol Neurodegener 2011;6:27.
82. Takagi K, Ito S, Miyazaki T, et al. Amyloid precursor protein in human breast cancer: An androgen-induced gene associated with cell proliferation. Cancer Sci 2013;104:1532-1538.
83. Luo W, Rodina A, Chiosis G. Heat shock protein 90: Translation from cancer to Alzheimer's disease treatment? BMC Neurosci 2008;9:S7.
84. Driver JA, Logroscino G, Buring JE, Gaziano JM, Kurth T. A prospective cohort study of cancer incidence following the diagnosis of Parkinson's disease. Cancer Epidemiol Biomarkers Prev 2007;16:1260-1265.
85. Pan T, Li X, Jankovic J. The association between Parkinson's disease and melanoma. Int J Cancer 2011;128:2251-2260.
86. Plun-Favreau H, Lewis PA, Hardy J, Martins LM, Wood NW. Cancer and neurodegeneration: Between the devil and the deep blue sea. PLoS Genet 2010;6:e1001257.
87. West AB, Dawson VL, Dawson TM. To die or grow: Parkinson's disease and cancer. Trends Neurosci 2005;28:348-352.
88. Kim RH, Mak TW. Tumours and tremors: How PTEN regulation underlies both. Br J Cancer 2006;94:620-624.
89. Kareus SA, Figueroa KP, Cannon-Albright LA, Pulst SM. Shared predispositions of Parkinsonism and cancer: A population-based pedigree-linked study. Arch Neurol 2012;69:1572-1577.
90. Raina AK, Monteiro MJ, McShea A, Smith MA. The role of cell cycle-mediated events in Alzheimer's disease. Int J Exp Pathol 1999;80:71-76.
91. Aliev G, Obrenovich ME, Tabrez S, et al. Link between cancer and Alzheimer disease via oxidative stress induced by nitric oxide-dependent mitochondrial DNA overproliferation and deletion. Oxid Med Cell Longev 2013;2013:962984.
92. Herrup K, Neve R, Ackerman SL, Copani A. Divide and die: Cell cycle events as triggers of nerve cell death. J Neurosci 2004;24:9232-9239.
93. Arendt T, Brückner MK. Linking cell-cycle dysfunction in Alzheimer's disease to a failure of synaptic plasticity. Biochim Biophys Acta 2007;1772:413-421.
94. Ogawa O, Zhu X, Lee H-G, et al. Ectopic localization of phosphorylated histone H3 in Alzheimer's disease: A mitotic catastrophe? Acta Neuropathol 2003;105:524-528.
95. Ogawa O, Lee H-g, Zhu X, et al. Increased p27, an essential component of cell cycle control, in Alzheimer's disease. Aging Cell 2003;2:105-110.
96. Arendt T. Neuronal dedifferentiation and degeneration in Alzheimer's disease. Biol Chem Hoppe Seyler 1993;374:911-912.
97. Saitoh T, Horsburgh K, Masliah E. Hyperactivation of signal transduction systems in Alzheimer's disease. Ann N Y Acad Sci 1993;695:34-41.
98. Gärtner U, Holzer M, Heumann R, Arendt T. Induction of p21ras in Alzheimer pathology. NeuroReport 1995;6:1441-1444.
99. McShea A, Lee H-g, Petersen RB, et al. Neuronal cell cycle re-entry mediates Alzheimer disease-type changes. Biochim Biophys Acta 2007;1772:467-472.
100. Raina AK, Zhu X, Rottkamp CA, Monteiro M, Takeda A, Smith MA. Cyclin' toward dementia: Cell cycle abnormalities and abortive oncogenesis in Alzheimer disease. J Neurosci Res 2000;61:128-133.
101. Qu L, Tang X. Bexarotene: A promising anticancer agent. Cancer Chemother Pharmacol 2010;65:201-205.
102. USFDA. www.accessdata.fda.gov/drugsatfda_docs/nda/99/21055_Targretin.cfm, 1999.
103. Farol LT, Hymes KB. Bexarotene: A clinical review. Expert Rev Anticancer Ther 2004;4:180-188.
104. Cramer PE, Cirrito JR, Wesson DW, et al. ApoE-directed therapeutics rapidly clear β-amyloid and reverse deficits in AD mouse models. Science 2012;335:1503-1506.
105. Park JW, Baek NS, Lee SC, et al. Preclinical efficacy testing for stomach and liver cancers. Cancer Res Treat 2014;46:186-193.
106. Senderowicz AM. The cell cycle as a target for cancer therapy: Basic and clinical findings with the small molecule inhibitors flavopiridol and UCN-01. Oncologist 2002;7:12-19.
107. Malumbres M, Pevarello P, Barbacid M, Bischoff JR. CDK inhibitors in cancer therapy: What is next? Trends Pharmacol Sci 2008;29:16-21.
108. Dhalla NS, Temsah RM, Netticadan T. Role of oxidative stress in cardiovascular diseases. J Hypertens 2000;18:655-673.
109. Kukreja RC, Hess ML. The oxygen free radical system: From equations through membrane-protein interactions to cardiovascular injury and protection. Cardiovasc Res 1992;26:641-655.
110. Manea A, Manea SA, Gafencu AV, Raicu M, Simionescu M. AP-1-dependent transcriptional regulation of NADPH oxidase in human aortic smooth muscle cells: Role of p22phox subunit. Arterioscler Thromb Vasc Biol 2008;28:878-885.
111. Elahi MM, Kong YX, Matata BM. Oxidative stress as a mediator of cardiovascular disease. Oxid Med Cell Longev 2009;2:259-269.
112. Simionescu M. Implications of early structural-functional changes in the endothelium for vascular disease. Arterioscler Thromb Vasc Biol 2007;27:266-274.
113. Cai H, Harrison DG. Endothelial dysfunction in cardiovascular diseases: The role of oxidant stress. Circ Res 2000;87:840-844.
114. van Empel VPM, Bertrand ATA, Hofstra L, Crijns HJ, Doevendans PA, De Windt LJ. Myocyte apoptosis in heart failure. Cardiovasc Res 2005;67:21-29.
115. Ottaviani G, Lavezzi AM, Rossi L, Matturri L. Proliferating cell nuclear antigen (PCNA) and apoptosis in hyperacute and acute myocardial infarction. Eur J Histochem 1999;43:7-14.
116. Scheubel RJ, Bartling B, Simm A, et al. Apoptotic pathway activation from mitochondria and death receptors without caspase-3 cleavage in failing human myocardium: Fragile balance of myocyte survival? J Am Coll Cardiol 2002;39:481-488.
117. Strand BH, Langballe EM, Hjellvik V, et al. Midlife vascular risk factors and their association with dementia deaths: Results from a Norwegian prospective study followed up for 35 years. J Neurol Sci 2013;324:124-130.
118. Alonso A, Jacobs DR Jr, Menotti A, et al. Cardiovascular risk factors and dementia mortality: 40 years of follow-up in the Seven Countries Study. J Neurol Sci 2009;280:79-83.
119. Newman AB, Fitzpatrick AL, Lopez O, et al. Dementia and Alzheimer's disease incidence in relationship to cardiovascular disease in the Cardiovascular Health Study cohort. J Am Geriatr Soc 2005;53:1101-1107.
120. Barnes DE, Haight TJ, Mehta KM, Carlson MC, Kuller LH, Tager IB. Secondhand smoke, vascular disease, and dementia incidence: Findings from the cardiovascular health cognition study. Am J Epidemiol 2010;171:292-302.
121. Low L-F, Yap MHW, Brodaty H. Will testing for apolipoprotein E assist in tailoring dementia risk reduction? A review Neurosci Biobehav Rev 2010;34:408-437.
122. Bachman DL, Green RC, Benke KS, Cupples LA, Farrer LA, Group MS. Comparison of Alzheimer's disease risk factors in white and African American families. Neurology 2003;60:1372-1374.
123. Díaz-Ruiz C, Wang J, Ksiezak-Reding H, et al. Role of hypertension in aggravating abeta neuropathology of AD type and Tau-mediated motor impairment. Cardiovasc Psychiatry Neurol 2009;2009:107286.
124. Humpel C. Chronic mild cerebrovascular dysfunction as a cause for Alzheimer's disease? Exp Gerontol 2011;46:225-232.
125. Muqtadar H, Testai FD, Gorelick PB. The dementia of cardiac disease. Curr Cardiol Rep 2012;14:732-740.
126. Zesiewicz TA, Strom JA, Borenstein AR, et al. Heart failure in Parkinson's disease: Analysis of the United States medicare current beneficiary survey. Parkinsonism Relat Disord 2004;10:417-420.
127. Richards BJ. Q10 Boosts Energy, Nerves, Muscles & Metabolism, http://www.wellnessresources.com, 2014.
128. Chen Y, Dorn GW. PINK1- phosphorylated mitofusin 2 is a Parkin receptor for culling damaged mitochondria. Science 2013;340:471-475.
129. Weckman A, Di Ieva A, Rotondo F, et al. Autophagy in the endocrine glands. J Mol Endocrinol 2014;52:R151-R163.
130. Friedman JR, Nunnari J. Mitochondrial form and function. Nature 2014;505:335-343.
131. Scarffe LA, Stevens DA, Dawson VL, Dawson TM. Parkin and PINK1: Much more than mitophagy. Trends Neurosci 2014;37:315-324.
132. Stuebner E, Vichayanrat E, Low DA, Mathias CJ, Isenmann S, Haensch C-A. Twenty-four hour non-invasive ambulatory blood pressure and heart rate monitoring in Parkinson's disease. Front Neurol 2013;4:49.
133. Ziemssen T, Reichmann H. Treatment of dysautonomia in extrapyramidal disorders. Ther Adv Neurol Disord 2010;3:53-67.
134. Iodice FG, Thomas M, Walker I, Garside V, Elliott MJ. Analgesia in fast-track paediatric cardiac patients. Eur J Cardiothorac Surg 2011;40:610-613.